Renal Disease
Cancer clinical trials commonly use ‘two most inaccurate’ tests to measure kidney function
Most cancer clinical trials use inaccurate tests to evaluate kidney function when determining participant eligibility, according to results of a cross-sectional study.
Decision factors for pediatric kidney replacement therapies may differ from guidelines
Level of kidney function, rate of decline and type of renal disease are key factors influencing the decision to initiate kidney replacement therapy, whether dialysis or transplantation, for pediatric patients, according to study data.
FDA clears Fresenius Medical Care high-volume hemodiafiltration system for US trials
Fresenius Medical Care has received FDA 510(k) clearance for its 5008X Hemodialysis System, allowing for the start of U.S.-based clinical trials, according to a press release.
VIDEO: Rastogi discusses results of treating hyperkalemia with Lokelma
PHILADELPHIA — Treating hyperkalemia with Lokelma (sodium polystyrene sulfonate, AstraZeneca) increased odds of patients maintaining renin-angiotensin-aldosterone system inhibitors therapy, a speaker said.
Build trust, offer options when navigating statin intolerance for patients
Editor's Note: This is part 1 of a three-part Healio Exclusive series on navigating statin intolerance.
High renal crisis, interstitial lung disease prevalence with systemic sclerosis sine scleroderma
Dermatologists should be aware of cutaneous findings in patients with systemic sclerosis sine scleroderma due to the association of internal organ dysfunction, according to a study.
Novartis to expand renal pipeline with agreement to acquire Chinook Therapeutics
Novartis announced that the company has agreed to acquire Chinook Therapeutics to expand its renal pipeline, according to a company press release.
US Renal Care raises $328 million for innovation, value-based care
U.S. Renal Care announced it has raised $328 million in new capital, which it plans to use for growth and expansion.
VIDEO: Voclosporin seen as well tolerated in patients with lupus nephritis for 3 years
ORLANDO — In this video from ASN Kidney Week, Samir V. Parikh, MD, discusses the results of the AURORA 2 study.
Novel anticoagulant therapy receives fast track designation from FDA
Merck announced its investigational factor XI inhibitor to reduce risk for major thrombotic CV events in patients with end-stage renal disease has received fast track designation from the FDA.